Stock listing
Dusseldorf:DB0 Q32 Bio Inc. Aktie
German listing (Dusseldorf) of Q32 Bio Inc. · home listing NASDAQ:QTTB
Follow Q32 Bio Inc. into a list and get an email when it puts out news.
Home listing price · NASDAQ:QTTB
$8.34 USD -0.19 (-2.2%)
Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:QTTB
- Day range
- $8.23 – $8.59 USDNov 20, 2026
- Volume
- 476,717 sharesNov 20, 2026
- Market cap
- $249.6M USDAt the close on Nov 20, 2026 · price × 29.92M shares outstanding
- 52-week range
- $1.93 – $23.57 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $6.66M USDMedian day 506,100 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:QTTB · Home | $8.34 USD | -0.19 (-2.2%) | 476,717 | $8.36 | $8.59 | $8.23 | $8.53 | Close on Nov 20, 2026 |
| LSE:0T6G | $8.402 USD | -0.028 (-0.3%) | 34 | $8.16 | $8.402 | $8.16 | $8.43 | Close on Nov 20, 2026 |
| Frankfurt:DB0 | €7.535 EUR | -0.08 (-1.1%) | — | €7.20 | €7.535 | €7.20 | €7.615 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:QTTB · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $8.34 | -0.19 | -2.2% | $8.36 | $8.59 | $8.23 | 476,717 | |
| $8.53 | -0.10 | -1.2% | $8.585 | $9.08 | $8.50 | 261,838 | |
| $8.63 | +0.34 | +4.1% | $8.27 | $8.73 | $8.06 | 621,205 | |
| $8.29 | -0.42 | -4.8% | $8.66 | $8.73 | $8.251 | 344,084 | |
| $8.71 | -0.11 | -1.2% | $8.83 | $8.86 | $8.45 | 243,793 | |
| $8.82 | -0.38 | -4.1% | $9.15 | $9.15 | $8.53 | 355,589 | |
| $9.20 | -0.13 | -1.4% | $9.39 | $9.44 | $9.13 | 236,085 | |
| $9.33 | -0.01 | -0.1% | $9.21 | $9.74 | $9.21 | 324,308 | |
| $9.34 | +0.09 | +1.0% | $9.35 | $9.65 | $9.01 | 413,223 | |
| $9.25 | +0.40 | +4.5% | $8.83 | $9.34 | $8.83 | 214,625 | |
| $8.85 | -0.12 | -1.3% | $8.91 | $8.93 | $8.23 | 583,246 | |
| $8.97 | +0.21 | +2.4% | $8.865 | $9.17 | $8.52 | 215,502 | |
| $8.76 | +0.05 | +0.6% | $8.68 | $9.035 | $8.68 | 175,200 | |
| $8.71 | -0.20 | -2.2% | $8.89 | $9.00 | $8.545 | 246,692 | |
| $8.91 | +0.04 | +0.5% | $8.87 | $8.98 | $8.53 | 268,080 | |
| $8.87 | -0.19 | -2.1% | $9.20 | $9.349 | $8.86 | 317,788 | |
| $9.06 | +0.35 | +4.0% | $8.65 | $9.11 | $8.51 | 409,200 | |
| $8.71 | +0.26 | +3.1% | $8.52 | $8.82 | $8.429 | 692,575 | |
| $8.45 | -0.20 | -2.3% | $8.60 | $8.825 | $8.39 | 563,686 | |
| $8.65 | -0.15 | -1.7% | $8.80 | $8.835 | $8.30 | 404,000 | |
| $8.80 | +0.13 | +1.5% | $8.67 | $9.01 | $8.60 | 363,600 | |
| $8.67 | +0.05 | +0.6% | $8.62 | $8.81 | $8.55 | 322,100 | |
| $8.62 | +0.83 | +10.7% | $7.79 | $8.84 | $7.79 | 506,100 | |
| $7.79 | +0.27 | +3.6% | $7.52 | $7.94 | $7.52 | 609,900 | |
| $7.52 | -0.25 | -3.2% | $7.82 | $7.82 | $7.28 | 678,000 | |
| $7.77 | -0.24 | -3.0% | $8.01 | $8.29 | $7.72 | 625,300 | |
| $8.01 | -0.05 | -0.6% | $7.93 | $8.30 | $7.72 | 889,300 | |
| $8.06 | -0.68 | -7.8% | $8.69 | $8.69 | $7.89 | 719,800 | |
| $8.74 | +0.40 | +4.8% | $8.64 | $9.155 | $8.44 | 682,300 | |
| $8.34 | +0.25 | +3.1% | $8.125 | $8.46 | $7.94 | 854,600 | |
| $8.09 | +0.10 | +1.3% | $7.94 | $8.12 | $7.62 | 859,600 | |
| $7.99 | -0.12 | -1.5% | $8.00 | $8.07 | $7.83 | 569,600 | |
| $8.11 | -0.26 | -3.1% | $8.32 | $8.36 | $7.80 | 678,400 | |
| $8.37 | +0.14 | +1.7% | $8.09 | $8.56 | $7.81 | 954,800 | |
| $8.23 | -0.02 | -0.2% | $8.35 | $9.11 | $8.17 | 2,097,000 | |
| $8.25 | -0.02 | -0.2% | $8.36 | $8.85 | $7.75 | 3,085,900 | |
| $8.27 | -1.26 | -13.2% | $10.40 | $10.40 | $7.878 | 5,250,500 | |
| $9.53 | +0.30 | +3.3% | $9.32 | $9.665 | $9.164 | 914,800 | |
| $9.23 | +0.46 | +5.2% | $9.21 | $9.445 | $8.77 | 1,004,900 | |
| $8.77 | -0.45 | -4.9% | $9.20 | $9.20 | $8.74 | 514,800 | |
| $9.22 | -0.34 | -3.6% | $9.51 | $9.55 | $9.05 | 1,075,000 | |
| $9.56 | -1.01 | -9.6% | $10.58 | $10.58 | $9.50 | 828,400 | |
| $10.57 | +0.10 | +1.0% | $10.60 | $10.99 | $10.53 | 387,200 | |
| $10.47 | -0.07 | -0.7% | $10.57 | $10.75 | $10.30 | 359,000 | |
| $10.54 | -0.32 | -2.9% | $10.84 | $10.97 | $10.46 | 972,300 | |
| $10.86 | -0.12 | -1.1% | $11.14 | $11.17 | $10.69 | 384,000 | |
| $10.98 | -0.19 | -1.7% | $11.17 | $11.41 | $10.87 | 504,900 | |
| $11.17 | +0.26 | +2.4% | $10.77 | $11.29 | $10.51 | 602,500 | |
| $10.91 | -0.19 | -1.7% | $10.96 | $11.28 | $10.63 | 870,600 | |
| $11.10 | +0.38 | +3.5% | $10.82 | $11.27 | $10.45 | 1,824,300 | |
| $10.72 | -0.42 | -3.8% | $11.00 | $11.08 | $10.54 | 937,600 | |
| $11.14 | -0.55 | -4.7% | $11.61 | $11.95 | $11.07 | 488,700 | |
| $11.69 | -0.30 | -2.5% | $12.00 | $12.00 | $11.57 | 592,900 | |
| $11.99 | -0.81 | -6.3% | $12.60 | $12.70 | $11.50 | 851,500 | |
| $12.80 | -0.79 | -5.8% | $13.52 | $13.59 | $12.74 | 491,500 | |
| $13.59 | -0.77 | -5.4% | $14.42 | $14.55 | $13.35 | 434,600 | |
| $14.36 | -0.51 | -3.4% | $14.77 | $14.77 | $14.18 | 331,400 | |
| $14.87 | -0.16 | -1.1% | $14.85 | $15.32 | $14.75 | 349,900 | |
| $15.03 | -1.12 | -6.9% | $15.91 | $16.25 | $14.92 | 353,400 | |
| $16.15 | -0.03 | -0.2% | $16.08 | $16.30 | $15.93 | 203,300 | |
| $16.18 | -0.14 | -0.9% | $16.13 | $16.52 | $15.80 | 327,100 | |
| $16.32 | -0.04 | -0.2% | $16.36 | $16.98 | $16.06 | 599,089 | |
| $16.36 | +0.39 | +2.4% | $16.50 | $16.66 | $15.50 | 691,058 | |
| $15.97 | +0.11 | +0.7% | $15.89 | $16.29 | $15.72 | 341,400 | |
| $15.86 | +0.02 | +0.1% | $15.80 | $16.15 | $15.51 | 389,100 |
Splits
1 split · NASDAQ:QTTB · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-18 | Consolidation |
- Ticker
- Dusseldorf:DB0
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- Dusseldorf
- Currency
- EUR
What changed lately
Latest news release · Nov 11, 2026
Q32 Bio to Participate in the 2026 Jefferies Global Healthcare Conference in London
Latest deck · Sep 30, 2026
EADV Congress 2026
Conference · 16 slides
Latest news
Q32 Bio to Participate in the 2026 Jefferies Global Healthcare Conference in London
Nov 11, 2026
Closed $9.20 (-1.4%) on Nov 11, 2026
Q32 Bio Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Nov 4, 2026
Closed $8.97 (+2.4%) on Nov 4, 2026
Q32 Bio Presents Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata in a Late-Breaker at the European Academy of Dermatology and Venereology Congress 2026
Sep 30, 2026
Closed $8.27 (-13.2%) on Sep 30, 2026
Q32 Bio Announces Upcoming Late-Breaking Presentation of Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata at the European Academy of Dermatology and Venereology Congress 2026
Sep 21, 2026
Closed $10.47 (-0.7%) on Sep 21, 2026
Q32 Bio Appoints José Trevejo, M.D., Ph.D., as Chief Medical Officer and Ellie Hershberger, Pharm.D., as Chief Development Officer
Sep 14, 2026
Closed $10.91 (-1.7%) on Sep 14, 2026
Q32 Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Aug 5, 2026
Closed $16.49 (+2.1%) on Aug 5, 2026
Q32 Bio Announces Pricing of $200 Million Public Offering of Common Stock and Pre-Funded Warrants
Jul 14, 2026
Closed $15.70 (-15.0%) on Jul 15, 2026
Q32 Bio Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
Jul 13, 2026
Closed $18.46 (-13.7%) on Jul 14, 2026
Q32 Bio Announces Positive 36-Week Topline Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata
Jul 13, 2026
Closed $21.38 (+90.7%) on Jul 13, 2026
Q32 Bio to Report 36-Week Topline Results from Part B of SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata on July 13, 2026
Jul 10, 2026
Closed $21.38 (+90.7%) on Jul 13, 2026
Q32 Bio Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 18 in the last 12 months · 109 in all · newest Nov 11, 2026 · oldest 2020
- Decks
- 7 decks · latest Sep 30, 2026
Where Q32 Bio Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:QTTB · Home listing | NASDAQ | United States | USD |
| gettex:DB0 | gettex | Germany | EUR |
| Lang & Schwarz:A4ZZ0Z | Lang & Schwarz | Germany | EUR |
| LSE:0T6G | LSE | United Kingdom | USD |
| BOATS:QTTB | BOATS | United States | USD |
| Dusseldorf:DB0 · This page | Dusseldorf | Germany | EUR |
| Frankfurt:DB0 | Frankfurt | Germany | EUR |
| Munich:DB0 | Munich | Germany | EUR |
| Stuttgart:DB0 | Stuttgart | Germany | EUR |
| Tradegate:DB0 | Tradegate | Germany | EUR |
Valuation
P/E 7.7× against a median of 128×: the lowest of 3 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- −$35.66M USD
- P/E
- 7.7×
- EV/sales
- −0.7×
- EV/EBITDA
- −1.9×
- Price/book
- 0.9×
- Gross margin
- 99.5%
- Operating margin
- 34.1%
- Net margin
- 59.8%
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 0.59
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Q32 Bio Inc. · NASDAQ:QTTB | US$249.6M | −US$35.66M | 7.7× | −0.7× | −1.9× | 0.9× | 59.8% | 0.0× | 0.59 |
| OBI Pharma, Inc. · TPEX:4174 | US$258.4M | US$243.3M | n/a | 154× | n/a | 5.7× | n/a | 0.0× | n/a |
| TransThera Sciences (Nanjing). Inc. · HKEX:2617 | US$257.1M | US$119.1M | n/a | n/a | n/a | 1.9× | n/a | 0.0× | n/a |
| Eikon Therapeutics, Inc. · NASDAQ:EIKN | US$256.8M | US$44.67M | n/a | n/a | n/a | 0.7× | n/a | 0.7× | 1.91 |
| SAB Biotherapeutics, Inc. · NASDAQ:SABS | US$255.7M | US$156.5M | n/a | n/a | n/a | 1.2× | n/a | 0.0× | 1.19 |
| Evommune, Inc. · NYSE:EVMN | US$255.5M | US$86.86M | n/a | n/a | n/a | 1.0× | n/a | 0.0× | 0.96 |
| Editas Medicine, Inc. · NASDAQ:EDIT | US$253.1M | US$119.7M | n/a | 2.4× | n/a | 3.0× | −144.9% | 0.7× | 2.22 |
| Turn Therapeutics Inc. · NASDAQ:TTRX | US$247.5M | US$244.2M | n/a | n/a | n/a | 43.5× | n/a | 1.1× | 1.54 |
| Mabpharm Limited · HKEX:2181 | US$247.3M | US$279.5M | 29.6× | 3.0× | 28.9× | 8.5× | 8.8% | 1.6× | n/a |
| Lexeo Therapeutics, Inc. · NASDAQ:LXEO | US$245.1M | US$56.52M | n/a | n/a | n/a | 1.1× | n/a | 0.0× | 1.62 |
| Shandong Boan Biotechnology Company., Limited. Class H · HKEX:6955 | US$242.7M | US$92.94M | 226× | 0.8× | 4.6× | 0.6× | 0.9% | 0.0× | n/a |
| Median of the others | US$254.3M | US$119.4M | 128× | 2.7× | 16.8× | 1.6× | 0.9% | 0.0× | 1.58 |
Forecasts
6 strong buy · 1 buy · Analysts' consensus from EODHD, read Nov 19, 2026. Not 6ix's view and not investment advice.
- Price target
- 39.67 USD · Analysts' mean
- EPS, year to Dec 2026
- -1.39 · 7 analysts
- Revenue, year to Dec 2026
- 333.3K · 6 analysts
Team and board
| Officer | Role |
|---|---|
| Jodie Morrison | Chief Executive Officer |
| Lee Kalowski | PRESIDENT & CHIEF FINANCIAL OFFICER |
| Brendan Burns | Senior Director, Investor Relations and Corporate Communications |
| David Appugliese | Senior Vice President, Head of People |
| Ellie Hershberger | CHIEF DEVELOPMENT OFFICER |
| José Trevejo | CHIEF MEDICAL OFFICER |
| Maria Marzilli | CHIEF BUSINESS OFFICER |
| Peter A. Merkel | Chief of Rheumatology |
| Shelia Violette | Founder and Chief Scientific Officer |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 4, 2026 · Before open | +2.4% |
| Q2 2026 | Aug 5, 2026 · Before open | +2.1% |
| Q1 2026 | May 5, 2026 · Before open | +2.0% |
| Q4 2025 | Mar 10, 2026 | +35.5% |
| Q3 2025 | Nov 13, 2025 · Before open | −9.1% |
| Q2 2025 | Aug 6, 2025 · Before open | −1.5% |
| Q1 2025 | May 8, 2025 · Before open | −1.9% |
| Q4 2024 | Mar 11, 2025 · Before open | −7.8% |
| Q3 2024 | Nov 7, 2024 · Before open | −1.1% |
| Q2 2024 | Aug 8, 2024 · Before open | −10.7% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 9, 2024 · Before open | +2.0% |
| Q4 2023 | Mar 13, 2024 · Before open | +1.4% |
| Q3 2023 | Nov 14, 2023 | −14.6% |
| Q2 2023 | Aug 14, 2023 | +2.6% |
| Q1 2023 | May 11, 2023 | +0.2% |
| Q4 2022 | Mar 9, 2023 | −16.9% |
| Q3 2022 | Nov 10, 2022 | +11.1% |
| Q2 2022 | Aug 15, 2022 | +4.7% |
| Q1 2022 | May 16, 2022 | +7.9% |
| Q4 2021 | Mar 23, 2022 | −7.5% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| EADV Congress 2026 | Conference | 16 slides | Sep 30, 2026 |
| Technical Presentation (July 2026) | Technical | 24 slides | Jul 13, 2026 |
| American Academy of Dermatology Late Breaker Session 2025 | Conference | 16 slides | Mar 8, 2025 |
| Investor Presentation (January 2025) | Investor deck | 34 slides | Jan 13, 2025 |
| Investor Presentation (December 2024) | Investor deck | 36 slides | Dec 11, 2024 |
| Homology Medicines — Merger or Acquisition (January 2024) | Merger or acquisition | 41 slides | Jan 26, 2024 |
| Homology Medicines — Merger or Acquisition (November 2023) | Merger or acquisition | 41 slides | Nov 16, 2023 |
Financings
| Raise | Date |
|---|---|
| Public offering of common stock and pre-funded warrants Closed: US$200M raised · US$18.25 a share · Morgan Stanley +4 Dealers: Morgan Stanley (co-lead), Jefferies (co-lead), Cantor (co-lead), Oppenheimer & Co., H.C. Wainwright & Co. Use of proceeds: With existing cash, fund operations through topline Phase 3 results of the planned registration-directed bempikibart program in severe or very severe AA | Aug 5, 2026 |
| At-the-market programme of common stock Tranche closed: US$14.2M raised | May 5, 2026 |
| Registered direct offering of common stock and pre-funded warrants Announced: US$10.5M · US$3.9 a share Use of proceeds: Working capital, including research, clinical development and commercialization, and advancing bempikibart into future alopecia areata trials | Feb 17, 2026 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Went public as Homology Medicines, Inc. Priced at US$16.00 a share on Mar 27, 2018.
- Price
- US$16.00 a share
- Shares offered
- 9,000,000 shares of common stock
- Offering size
- US$144 million
- Underwriters' option
- Up to 1,350,000 more shares
- Underwriters
- BofA Merrill Lynch, Cowen, Evercore ISI, BTIG · In the order on the cover
- Shares delivered
- On or about Apr 2, 2018
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Dec 22, 2017 |
| Filed publicly | Mar 2, 2018 |
| Amended 3 times | Newest Mar 27, 2018 |
| Shares registered with an exchange | Mar 19, 2018 |
| Declared effective by the SEC | Mar 27, 2018 |
| Final prospectus, with the price | Mar 29, 2018 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Mar 29, 2018 |
| EFFECT · Notice that a registration is effective | Mar 27, 2018 |
| FWP · Free writing prospectus | Mar 27, 2018 |
| S-1/A · Registration statement, amended | Mar 27, 2018 |
| CORRESP · Letter to the SEC | Mar 23, 2018 |
| CORRESP · Letter to the SEC | Mar 23, 2018 |
| S-1/A · Registration statement, amended | Mar 23, 2018 |
| CERT · Exchange's certificate of listing | Mar 22, 2018 |
| S-1/A · Registration statement, amended | Mar 19, 2018 |
| 8-A12B · Registration of shares for listing on an exchange | Mar 19, 2018 |
All 20 filings
| Filing | Filed |
|---|---|
| CORRESP · Letter to the SEC | Mar 14, 2018 |
| UPLOAD · Letter from the SEC | Mar 6, 2018 |
| S-1 · Registration statement | Mar 2, 2018 |
| DRSLTR · Letter to the SEC with a draft | Feb 23, 2018 |
| DRS/A · Draft registration statement, amended | Feb 23, 2018 |
| UPLOAD · Letter from the SEC | Feb 12, 2018 |
| DRSLTR · Letter to the SEC with a draft | Jan 30, 2018 |
| DRS/A · Draft registration statement, amended | Jan 30, 2018 |
| UPLOAD · Letter from the SEC | Jan 19, 2018 |
| DRS · Draft registration statement | Dec 22, 2017 |
Open IPO · From the cover of the final prospectus (424B4) filed Mar 29, 2018
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 53.7M | 0 | -6.65M | 3.21M | 34.0M | 2.70M | 1.67M | 3.68M | ||
| Cost of revenue | 391.0K | 487.0K | 499.0K | 2.60M | 9.54M | 684.2K | 239.8K | |||
| Gross profit | 53.7M | -487.0K | -6.65M | 6.65M | 24.4M | 2.70M | 1.67M | 5.32M | -684.2K | -239.8K |
| Research and development | 19.2M | 48.1M | 31.7M | 98.4M | 93.1M | 100.4M | 89.4M | 47.9M | 21.4M | 5.69M |
| Selling, general and administrative | 17.7M | 18.0M | 9.88M | 10.1M | 6.76M | |||||
| Operating income | 16.9M | -66.1M | -48.3M | -133.3M | -95.9M | -130.3M | -109.9M | -59.9M | -29.7M | -10.0M |
| Depreciation and amortization | 391.0K | 487.0K | 499.0K | 1.29M | 8.35M | 7.96M | 6.32M | 1.29M | 684.0K | 239.8K |
| EBITDA | 17.3M | -65.6M | -47.8M | -132.0M | -87.6M | -122.3M | -103.6M | -58.6M | -29.0M | -9.76M |
| Interest expense | 1.10M | 1.10M | 1.50M | |||||||
| Income before tax | 29.8M | -46.1M | -87.1M | 1.20M | -95.8M | -128.7M | -103.9M | -55.6M | -30.0M | -8.05M |
| Income tax | 0 | 21.0K | 318.0K | 715.0K | 0 | 0 | 0 | 0 | 0 | 2 |
| Net income | 29.8M | -47.7M | -53.7M | -5.00M | -95.8M | -128.7M | -103.9M | -55.6M | -30.0M | -8.05M |
| Earnings per share, basic | 2.42 | -5.12 | -153.96 | -0.09 | -1.73 | -2.80 | -2.47 | -1.95 | -12.10 | -3.87 |
| Earnings per share, diluted | 2.42 | -6.58 | -153.96 | -0.09 | -1.73 | -2.80 | -2.47 | -1.95 | -12.10 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 48.3M | 78.0M | 25.6M | 34.0M | 108.4M | 217.4M | 53.8M | 38.2M | 51.6M | 11.4M |
| Short-term investments | 0 | 0 | 141.0M | 47.5M | 0 | 208.6M | 176.5M | 78.1M | ||
| Receivables | 555.0K | 755.0K | 1.06M | 909.0K | 400.0K | 400.0K | 800.0K | 113.3K | ||
| Inventory | 1.75M | 769.0K | 1 | |||||||
| Current assets | 55.0M | 81.9M | 28.7M | 181.0M | 191.9M | 219.6M | 266.6M | 221.7M | 131.6M | 12.0M |
| Property, plant and equipment | 979.0K | 1.37M | 1.78M | 1.08M | 2.25M | 37.0M | 42.7M | 35.6M | 3.15M | |
| Total assets | 61.8M | 92.3M | 47.1M | 228.5M | 211.7M | 263.7M | 310.6M | 259.1M | 137.5M | 14.2M |
| Accounts payable | 879.0K | 2.99M | 3.47M | 1.14M | 2.37M | 4.72M | 2.61M | 15.7M | 2.54M | 893.7K |
| Current liabilities | 11.3M | 16.5M | 14.1M | 22.6M | 17.2M | 22.7M | 12.4M | 22.5M | 8.86M | 6.38M |
| Long-term debt | 3.47M | 9.56M | 43.2M | 5.07M | 4.97M | |||||
| Total debt | 15.3M | 18.9M | 50.8M | 29.9M | 23.9M | 15.4M | ||||
| Total liabilities | 19.8M | 86.7M | 118.5M | 50.5M | 42.1M | 67.7M | 52.1M | 62.7M | 39.2M | 6.72M |
| Shareholders' equity | 42.0M | 5.67M | -182.9M | -130.7M | 169.7M | 196.0M | 258.5M | 196.4M | -39.5M | 7.50M |
| Shares outstanding | 12.9M | 12.2M | 359.6K | 57.5M | 57.2M | 50.3M | 45.1M | 37.4M | 2.64M | 2.08M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -33.5M | -67.7M | -18.7M | -113.7M | -109.8M | -94.3M | -91.4M | -42.6M | 6.48M | -8.48M |
| Capital spending | 0 | -75.0K | -5.00K | -1.28M | -2.40M | -3.73M | -21.8M | -24.9M | -1.96M | -1.99M |
| Free cash flow | -33.5M | -67.8M | -18.7M | -114.9M | -112.1M | -98.1M | -113.2M | -67.5M | 4.52M | -10.5M |
| Cash from investing | 7.00M | 19.9M | -5.00K | 36.7M | -50.8M | 204.9M | -51.8M | -121.8M | -81.5M | -2.27M |
| Cash from financing | -3.13M | 95.1M | 406.0K | 596.0K | 52.2M | 53.1M | 158.2M | 151.0M | 115.2M | 378.3K |
| Share buybacks | -17.5K | |||||||||
| Change in cash | -29.7M | 47.3M | 5.28M | -76.3M | -108.4M | 163.7M | 15.1M | -13.4M | 40.2M | -10.4M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 16, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 6, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 6, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 4, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 4, 2026 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Oct 28, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Oct 14, 2026 | Insider trade | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Oct 14, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 14, 2026 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Oct 9, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Sep 30, 2026 | Current report | SEC |
| 8-K · Current report | Sep 14, 2026 | Current report | SEC |
| 4 · Change in ownership | Aug 27, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 27, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 27, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 5, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 5, 2026 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jul 31, 2026 | Big-stake notice | SEC |
| EFFECT · Notice that a registration is effective | Jul 29, 2026 | Other filings | SEC |
| 424B3 · Prospectus | Jul 28, 2026 | Offer document | SEC |
| 4/A · Change in ownership, amended | Jul 21, 2026 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Jul 21, 2026 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Jul 21, 2026 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Jul 21, 2026 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Jul 21, 2026 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Jul 21, 2026 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Jul 21, 2026 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Jul 21, 2026 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Jul 20, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jul 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 20, 2026 | Insider trade | SEC |
| S-3 · Registration statement | Jul 17, 2026 | Offer document | SEC |
| 8-K · Current report | Jul 15, 2026 | Material contract | SEC |
| 424B5 · Prospectus | Jul 15, 2026 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Jul 14, 2026 | Other filings | SEC |
| 424B5 · Prospectus | Jul 13, 2026 | Offer document | SEC |
| 8-K · Current report | Jul 13, 2026 | Current report | SEC |
| 8-K · Current report | Jul 13, 2026 | Current report | SEC |
| SCHEDULE 13G · Big-stake notice | Jul 10, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jul 6, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jul 2, 2026 | Insider trade | SEC |
| S-3 · Registration statement | Jun 25, 2026 | Offer document | SEC |
| 4 · Change in ownership | Jun 16, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 16, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 16, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 16, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 16, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 16, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 16, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 16, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 16, 2026 | Meeting outcome | SEC |
| 3 · Initial statement of ownership | Jun 8, 2026 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Jun 4, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Jun 4, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jun 1, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 1, 2026 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Jun 1, 2026 | Big-stake notice | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | May 28, 2026 | Big-stake notice | SEC |
| 8-K · Current report | May 27, 2026 | Material contract | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | May 15, 2026 | Big-stake notice | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | May 6, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 6, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 5, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 5, 2026 | Results | SEC |
| ARS · Annual report to shareholders | Apr 30, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 30, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 30, 2026 | Meeting notice | SEC |
| 8-K · Current report | Apr 24, 2026 | Current report | SEC |
| 424B5 · Prospectus | Apr 24, 2026 | Offer document | SEC |
| 8-K · Current report | Mar 27, 2026 | Material contract | SEC |
| 424B5 · Prospectus | Mar 27, 2026 | Offer document | SEC |
| 4 · Change in ownership | Mar 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 20, 2026 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Mar 12, 2026 | Big-stake notice | SEC |
| S-8 · Registration statement for employee plans | Mar 10, 2026 | Offer document | SEC |
| 10-K · Annual report | Mar 10, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 10, 2026 | Results | SEC |
| 4 · Change in ownership | Feb 27, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 27, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 27, 2026 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 20, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 19, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Feb 17, 2026 | Material contract | SEC |
| 424B5 · Prospectus | Feb 17, 2026 | Offer document | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 13, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 30, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 30, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 30, 2026 | Insider trade | SEC |
| 8-K · Current report | Dec 19, 2025 | Management or board change | SEC |
| 4 · Change in ownership | Dec 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 4, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 2, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 2, 2025 | Other filings | SEC |
| 8-K · Current report | Dec 1, 2025 | Acquisition or disposal | SEC |
| 10-Q · Quarterly report | Nov 13, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 13, 2025 | Results | SEC |
| 4 · Change in ownership | Oct 27, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 27, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 27, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 27, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 27, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 27, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 27, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 27, 2025 | Insider trade | SEC |
| 8-K · Current report | Oct 21, 2025 | Current report | SEC |
| 4 · Change in ownership | Aug 28, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 28, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 28, 2025 | Insider trade | SEC |
| UPLOAD · Letter from the SEC | Aug 28, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Aug 26, 2025 | Other filings | SEC |
| 10-Q · Quarterly report | Aug 6, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 6, 2025 | Results | SEC |
| CORRESP · Letter to the SEC | Jul 31, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Jul 30, 2025 | Other filings | SEC |
| 8-K · Current report | Jun 25, 2025 | Management or board change | SEC |
| 8-K · Current report | Jun 17, 2025 | Meeting outcome | SEC |
| 8-K · Current report | May 23, 2025 | Current report | SEC |
| 10-Q · Quarterly report | May 8, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 8, 2025 | Results | SEC |
| ARS · Annual report to shareholders | Apr 29, 2025 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 29, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 29, 2025 | Meeting notice | SEC |
| 8-K · Current report | Apr 25, 2025 | Management or board change | SEC |
| EFFECT · Notice that a registration is effective | Apr 22, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Apr 17, 2025 | Other filings | SEC |
| EFFECT · Notice that a registration is effective | Apr 17, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Apr 16, 2025 | Other filings | SEC |
| POS AM · Amendment to an effective registration | Apr 11, 2025 | Offer document | SEC |
| S-3 · Registration statement | Apr 11, 2025 | Offer document | SEC |
| PRE 14A · Preliminary proxy statement | Apr 11, 2025 | Meeting notice | SEC |
| SCHEDULE 13G · Big-stake notice | Apr 8, 2025 | Big-stake notice | SEC |
| S-8 · Registration statement for employee plans | Mar 11, 2025 | Offer document | SEC |
| 424B3 · Prospectus | Mar 11, 2025 | Offer document | SEC |
| 10-K · Annual report | Mar 11, 2025 | Annual report | SEC |
| 8-K · Current report | Mar 11, 2025 | Results | SEC |
| 424B3 · Prospectus | Mar 10, 2025 | Offer document | SEC |
| 8-K · Current report | Mar 10, 2025 | Current report | SEC |
| 4 · Change in ownership | Feb 27, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 27, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 27, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 27, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 26, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 26, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 26, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 26, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 26, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 26, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 26, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 26, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| 424B3 · Prospectus | Feb 10, 2025 | Offer document | SEC |
| 8-K · Current report | Feb 10, 2025 | Current report | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 10, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Jan 13, 2025 | Current report | SEC |
| 424B3 · Prospectus | Dec 11, 2024 | Offer document | SEC |
| 8-K · Current report | Dec 11, 2024 | Current report | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Nov 13, 2024 | Big-stake notice | SEC |
| 424B3 · Prospectus | Nov 7, 2024 | Offer document | SEC |
| 10-Q · Quarterly report | Nov 7, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 7, 2024 | Results | SEC |
| SC 13G/A · Big-stake notice, amended | Oct 25, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Oct 16, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 10, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 30, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 27, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 14, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 14, 2024 | Insider trade | SEC |
| 424B3 · Prospectus | Aug 8, 2024 | Offer document | SEC |
| 10-Q · Quarterly report | Aug 8, 2024 | Quarterly report | SEC |
| 8-K · Current report | Aug 8, 2024 | Results | SEC |
| 424B3 · Prospectus | Jul 9, 2024 | Offer document | SEC |
| 8-K · Current report | Jul 9, 2024 | Current report | SEC |
| S-8 · Registration statement for employee plans | May 31, 2024 | Offer document | SEC |
| SC 13G/A · Big-stake notice, amended | May 13, 2024 | Big-stake notice | SEC |
| 424B3 · Prospectus | May 9, 2024 | Offer document | SEC |
| 10-Q · Quarterly report | May 9, 2024 | Quarterly report | SEC |
| 8-K · Current report | May 9, 2024 | Results | SEC |
| EFFECT · Notice that a registration is effective | Apr 30, 2024 | Other filings | SEC |
| 424B3 · Prospectus | Apr 29, 2024 | Offer document | SEC |
| CORRESP · Letter to the SEC | Apr 25, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Apr 25, 2024 | Other filings | SEC |
| 4 · Change in ownership | Apr 23, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Apr 23, 2024 | Insider trade | SEC |
| S-1 · Registration statement | Apr 19, 2024 | Offer document | SEC |
| 10-K/A · Annual report, amended | Apr 12, 2024 | Annual report | SEC |
| SC 13D · Big-stake notice | Apr 4, 2024 | Big-stake notice | SEC |
| SC 13D · Big-stake notice | Apr 1, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Mar 29, 2024 | Big-stake notice | SEC |
| SC 13D · Big-stake notice | Mar 28, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Mar 27, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 27, 2024 | Insider trade | SEC |
This page holds 200 of 594 filings. Open Filings
Cap table
Built by 6ix from Q32 Bio Inc.’s releases · as of Oct 31, 2026
- Common shares
- 29,923,882
- Fully diluted
- 29,923,882
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 29,923,882 | Oct 31, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Oct 31, 2026 | 29,923,882 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| James Flynn Other companies: Lite Strategy, Inc. (Director · Since at least Oct 31, 2023); Nuvalent, Inc. (Director · Since at least Jul 28, 2021); Larimar Therapeutics, Inc. (Director · Since at least May 28, 2020); Synlogic Inc (Director · Mar 19, 2024 – Apr 26, 2025 · Past); BiomX Inc. (Director · Mar 15, 2024 – Apr 21, 2025 · Past); Oruka Therapeutics, Inc. (Director · Jan 30, 2024 – Jan 30, 2024 · Past); RiceBran Technologies (Director · Jan 3, 2024 – Jan 3, 2024 · Past); CareMax Inc (Director · Nov 17, 2022 – Nov 17, 2023 · Past); ARS Pharmaceuticals, Inc. (Director · Nov 8, 2022 – Nov 8, 2022 · Past); Da32 Life Science Tech Acquisition Corp (Director · Jul 27, 2021 – Jul 28, 2023 · Past); Oncorus Inc (Director · Oct 1, 2020 – Feb 17, 2021 · Past); Acutus Medical Inc. (Director · Aug 5, 2020 – Jan 27, 2025 · Past); Deerfield Healthcare Technology Acquisitions Corp (Director · Jul 16, 2020 – Jul 21, 2020 · Past); AdaptHealth Corp. (Director · Feb 15, 2018 – Nov 8, 2019 · Past); Alpine Immune Sciences Inc (Director · Sep 12, 2016 – Sep 12, 2016 · Past); AveXis Inc (Director · Sep 3, 2015 – Feb 10, 2016 · Past) | Director · Mar 27, 2018 – Jun 6, 2019 · Past |
| Kathleen LaPorte Other companies: 89bio Inc (Director · Since at least Nov 1, 2021); CERo Therapeutics Holdings, Inc. (Director · Since at least Oct 5, 2021); Bolt Biotherapeutics, Inc. (Director · Since at least Feb 4, 2021); Precipio, Inc. (Director · Since at least Aug 7, 2018); Paratek Pharmaceuticals Inc (Director · Jan 30, 2009 – Jan 24, 2012 · Past); Affymax Inc (Director · Dec 14, 2006 – Dec 14, 2012 · Past); eHealth, Inc. (Director · Oct 12, 2006 – Oct 12, 2006 · Past); Ista Pharmaceuticals Inc (Director · Jun 22, 2006 – Apr 13, 2011 · Past); Adeza Biomedical Corp (Director · Jun 6, 2006 – Jun 6, 2006 · Past); Vnus Medical Technologies Inc (Director · May 25, 2006 – May 23, 2008 · Past) | Director · Since at least Mar 25, 2024 |
| Mark Iwicki Other companies: Inhibikase Therapeutics, Inc. (Chief Executive Officer - Inhibikase · Since at least Feb 14, 2025); Third Harmonic Bio Inc. (Director · Since at least Sep 14, 2022); Akero Therapeutics Inc (Director · Since at least Jun 19, 2019); Kala Bio, Inc. (Director · Since at least Jul 19, 2017); Jade Biosciences, Inc. (Director · Apr 2, 2021 – Jun 5, 2024 · Past); Pulmatrix, Inc. (Director · Mar 20, 2017 – Jan 28, 2021 · Past); Aimmune Therapeutics Inc (Director · May 25, 2016 – Oct 10, 2020 · Past) | Director · Since at least Mar 25, 2024 |
| Mary Thistle Other companies: Aktis Oncology, Inc. (Independent Director · Since at least Jan 8, 2026); Cullinan Therapeutics, Inc. (Chair of the Compensation Committee · Since at least Aug 8, 2024); Vigil Neuroscience Inc (Director · Since at least Apr 18, 2022); Entrada Therapeutics, Inc. (Industry Leader and Independent Director · Since at least Oct 28, 2021); Alaunos Therapeutics, Inc. (Director · Nov 15, 2020 – Jun 6, 2023 · Past); Dimension Therapeutics (Chief Operating Officer · Feb 1, 2017 – Nov 7, 2017 · Past) | Director · Since at least Mar 27, 2018 |
| Steven Gillis Other companies: Kardigan, Inc. (Director · Since at least Jun 22, 2026); Takeda Pharmaceutical Co. Ltd. (Director · Since at least Mar 18, 2026); Metsera, Inc. (Director · Since at least Nov 13, 2025); Codiak BioSciences Inc (Director · Oct 13, 2020 – Feb 16, 2023 · Past); VBI Vaccines Inc. (Director · Jun 14, 2019 – Jul 27, 2023 · Past); Pulmatrix, Inc. (Director · May 16, 2019 – Aug 28, 2020 · Past) | Director · Jun 6, 2019 – Jun 14, 2023 · Past |
| Jodie Morrison Other companies: Verve Therapeutics Inc (Director · Since at least Jun 26, 2024); Akebia Therapeutics, Inc. (Director · Dec 12, 2018 – Jun 6, 2019 · Past); Rein Therapeutics, Inc. (Director · Jun 28, 2017 – Jun 15, 2022 · Past); Keryx Biopharmaceuticals Inc (Interim CEO, Director · Jun 21, 2016 – Dec 12, 2018 · Past); Eledon Pharmaceuticals, Inc. (Director · Sep 16, 2014 – Jun 30, 2017 · Past) | Chief Executive Officer · Since at least Mar 25, 2024 |
| Alise Reicin Other companies: Immatics N.V. (Director · Since at least Mar 18, 2026); Tectonic Therapeutic, Inc. (President and CEO, Director · Since at least Jun 20, 2024); Sana Biotechnology, Inc. (Director · Since at least Feb 3, 2021); Celgene Corporation (PRES., GLOBAL CLINICAL DEV. · Nov 1, 2018 – Nov 20, 2019 · Past) | Director · Jul 11, 2019 – Jun 14, 2023 · Past |
| Arthur Tzianabos Other companies: Stoke Therapeutics, Inc. (Chairman · Since at least Jun 18, 2019); Akouos Inc (Director · Jun 25, 2020 – Nov 30, 2022 · Past); BIND Therapeutics Inc (Director · Oct 9, 2015 – Jun 21, 2016 · Past); Tempest Therapeutics, Inc. (President and CSO · Sep 3, 2013 – Dec 3, 2015 · Past) | Director · Since at least Mar 27, 2018 |
| Isaac Manke Other companies: Rainier Acquisition Corporation (Director · Since at least Aug 26, 2026); Addex Therapeutics Ltd (Director · Since at least Mar 18, 2026); OnKure Therapeutics, Inc. (Director · Since at least Oct 4, 2024); Chardan Healthcare Acquisition 2 Corp (Director · Apr 23, 2020 – Apr 23, 2020 · Past) | Director · Since at least Mar 25, 2024 |
| Mahendra Shah Other companies: Verona Pharma plc (Director · Since at least Jan 1, 2021); Impel Neuropharma Inc (Director · Apr 22, 2021 – Jul 11, 2021 · Past); Bolt Biotherapeutics, Inc. (Director · Feb 4, 2021 – Jun 12, 2024 · Past); Soleno Therapeutics, Inc. (Director · Jul 6, 2017 – Jun 11, 2018 · Past) | Director · Mar 27, 2018 – Apr 2, 2018 · Past |
All 38 people
| Person | Seat |
|---|---|
| Bradford Smith Other companies: Lyra Therapeutics, Inc. (Board Director · Since at least Apr 30, 2020); Ocular Therapeutix, Inc. (CFO and Treasurer · Jul 24, 2014 – Jan 31, 2017 · Past); NeuroMetrix Inc (Chief Financial Officer · Jan 4, 2006 – Apr 1, 2008 · Past) | See remarks · Mar 27, 2018 – Feb 23, 2023 · Past |
| Matthew R Patterson Other companies: Vor Biopharma Inc. (Director · Feb 4, 2021 – May 22, 2025 · Past); 5 01 Acquisition Corp (Director · Oct 13, 2020 – Oct 16, 2020 · Past); Audentes Therapeutics Inc (Chief Executive Officer, Director · Jul 19, 2016 – Jan 15, 2020 · Past) | Director · Mar 27, 2018 – Jun 14, 2023 · Past |
| Cameron Wheeler Other companies: Nuvalent, Inc. (Director · Since at least Jul 28, 2021); Oncorus Inc (Director · Oct 1, 2020 – Oct 1, 2020 · Past) | Director · Mar 27, 2018 – Jun 6, 2019 · Past |
| David Grayzel Other companies: Jade Biosciences, Inc. (Director · Feb 1, 2021 – Jun 5, 2024 · Past); Surface Oncology Inc (Director · Apr 18, 2018 – Sep 8, 2023 · Past) | Director · Since at least Mar 25, 2024 |
| Jeffrey V Poulton Other companies: CervoMed Inc. (Director · Since at least Aug 16, 2023); Alnylam Pharmaceuticals, Inc. (EVP, Chief Financial Officer · Since at least Aug 13, 2019) | Director · Jul 21, 2020 – Jun 14, 2023 · Past |
| Lee Kalowski Other companies: Bicycle Therapeutics PLC (President and CFO · May 22, 2019 – Apr 3, 2023 · Past); Eledon Pharmaceuticals, Inc. (Chief Financial Officer · Sep 16, 2014 – Dec 15, 2015 · Past) | PRESIDENT & CHIEF FINANCIAL OFFICER · Since at least Mar 25, 2024 |
| Richard J Gregory Other companies: ProMIS Neurosciences Inc. (Director · Jul 7, 2022 – Jul 7, 2022 · Past); ImmunoGen Inc (Executive VP & CSO · Jan 5, 2015 – Feb 22, 2019 · Past) | Director · Mar 27, 2018 – Jun 15, 2022 · Past |
| Sven Ante Lundberg Other companies: Vor Biopharma Inc. (Director · Feb 4, 2021 – May 22, 2025 · Past); CRISPR Therapeutics AG (Chief Scientific Officer · Oct 18, 2016 – Oct 24, 2016 · Past) | Director · Since at least Mar 25, 2024 |
| Jason Campagna Other companies: Intercept Pharmaceuticals Inc (Chief Medical Officer · Dec 1, 2019 – Jan 22, 2021 · Past) | Chief Medical Officer · Mar 25, 2024 – Feb 24, 2025 · Past |
| Julie Jordan Other companies: Neurogene Inc. (Chief Medical Officer · Since at least Jan 16, 2024) | Chief Medical Officer · Mar 7, 2023 – Aug 3, 2023 · Past |
| Bill Lundberg | Board Member · Nov 4, 2026 – Nov 4, 2026 · Past |
| Brendan Burns | Senior Director, Investor Relations and Corporate Communications · Since at least Nov 4, 2026 |
| Brian Kotzin | Board Member · Nov 4, 2026 – Nov 4, 2026 · Past |
| Charles Michaud Jr | See Remarks · Nov 15, 2023 – Mar 25, 2024 · Past |
| David Appugliese | Senior Vice President, Head of People · Since at least Nov 4, 2026 |
| Diyong Xu | Director · Since at least Mar 25, 2024 |
| Ellie Hershberger | CHIEF DEVELOPMENT OFFICER · Since at least Sep 14, 2026 |
| Gabriel Cohn | Chief Medical Officer · Dec 2, 2019 – Jan 1, 2022 · Past |
| John P. Atkinson | Board Member · Nov 4, 2026 – Nov 4, 2026 · Past |
| José Trevejo | CHIEF MEDICAL OFFICER · Since Sep 14, 2026 |
| Maria Marzilli | CHIEF BUSINESS OFFICER · Since at least Nov 5, 2026 |
| Michael Holers | Board Member · Nov 4, 2026 – Nov 4, 2026 · Past |
| Michael Lee Blum | Chief Commercial Officer · Mar 2, 2022 – Feb 23, 2023 · Past |
| Paul Alloway | See Remarks · Mar 2, 2022 – Mar 25, 2024 · Past |
| Peter A. Merkel | Chief of Rheumatology · Since at least Nov 5, 2026 |
| Shelia Violette | Founder and Chief Scientific Officer · Since at least Mar 25, 2024 |
| Simon Read | Board Member · Nov 4, 2026 – Nov 4, 2026 · Past |
| Siyamak Rasty | Chief Operating Officer · Mar 27, 2018 – Jul 9, 2019 · Past |
Log in to ask 6ix AI your own questions about Q32 Bio Inc.